HER2-positive Metastatic Breast Cancer Clinical Trials

41 clinical trials for HER2-positive Metastatic Breast Cancer across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer — RECRUITING
• HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer — RECRUITING · PHASE2
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — RECRUITING · PHASE1
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer — RECRUITING · PHASE2
• SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance — RECRUITING · NA
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease — RECRUITING · PHASE2
• Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer — RECRUITING · NA
• PRE-I-SPY Phase I/Ib Oncology Platform Program — RECRUITING · PHASE1
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd — RECRUITING · PHASE1
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial — RECRUITING · PHASE3
• A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer — TERMINATED · PHASE1
• A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07) — TERMINATED · PHASE2
• Testing a New Imaging Agent to Identify Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. — ACTIVE_NOT_RECRUITING · PHASE1
• ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) — ACTIVE_NOT_RECRUITING · PHASE2
• Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) — TERMINATED · PHASE3
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer — TERMINATED · PHASE2
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity — ACTIVE_NOT_RECRUITING
• ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors — TERMINATED · PHASE1
• ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors — COMPLETED · PHASE1
• ARX788 in HER2-positive Metastatic Breast Cancer Patients — NOT_YET_RECRUITING · PHASE2
• Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer — COMPLETED
• Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer — OTHER · NA
• A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases — OTHER · PHASE2
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer — WITHDRAWN · PHASE1
• Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. — OTHER · PHASE2
• A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer — OTHER · PHASE2
• Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer — TERMINATED
• A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer — OTHER · PHASE3
• ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases — OTHER · PHASE2
• Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab — OTHER
• Feasibility of a New Technology for Isolating Circulating Tumour Cells — OTHER · NA
• A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC — COMPLETED · PHASE1
• Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) — OTHER · PHASE3
• A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. — OTHER · PHASE3
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer — COMPLETED · PHASE1
• A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab — OTHER · PHASE1
• The Myocet/Lapatinib Study. ICORG 10-03, V5 — TERMINATED · PHASE1

Refine this search